Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.88 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728352 | 0.94 | HRH3 (1.00) | HRH3NPC1RAB9ACYP3A4TSHR | |
| Trifluoroacetic Acid SCHEMBL1730409 | 0.87 | HRH3 (0.77) | HRH3NPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL2994664 | 0.87 | HRH3 (0.87) | HRH3CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL1729710 | 0.86 | HRH3 (0.88) | HRH3CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL222825 | 0.86 | HRH3 (0.65) | HRH3CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL222603 | 0.85 | HRH3 (0.63) | HRH3RAB9A | |
| Trifluoroacetic Acid SCHEMBL223454 | 0.84 | HRH3 (0.62) | HRH3 | |
| Trifluoroacetic Acid SCHEMBL1730706 | 0.83 | HRH3 (0.88) | HRH3CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL1727893 | 0.83 | HRH3 (0.88) | HRH3 | |
| Trifluoroacetic Acid SCHEMBL2425231 | 0.83 | HRH3 (0.61) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222290-B2 | Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof | SANOFI (FR) | 2012-07-17 | — | — | US | disclosed |
| EP-2215058-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-11-23 | — | — | EP | disclosed |
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173908-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE UREAS AND THERAPEUTIC USE THEREOF | HRH3, HRH4, UTS2R | HRH3 1/4885NPC1 1261/4885RAB9A 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.